Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant vs Physician's Choice of Endocrine Therapy in ER+, HER2- Early Breast Cancer
NCT04961996Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 54
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Roche. Started Aug 2021; status: active, not recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04961996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961996.